Tetsu Maruyama is a Venture Partner in the Dementia Discovery Fund at SV Health Investors.
Tetsu is the Executive Director of the Alzheimer’s Disease Data Initiative (ADDI), (www.alzheimersdata.org). He began his career as an academic neuroscientist, holding faculty positions in the US and UK before moving to industry. Tetsu held leadership positions in central nervous system (CNS) drug discovery for Merck Sharp and Dohme in the UK and for GlaxoSmithKline in Singapore before becoming Head of Drug Discovery at Takeda Pharmaceuticals in 2010. In 2016 he joined the Dementia Discovery Fund as Chief Scientific Officer. Tetsu has been on the Boards of several privately held biotech companies and non-profit organizations focused on open science. He is a member of the World Dementia Council.
In his spare time, Tetsu enjoys playing bass guitar and singing, becomes overly involved in watching all kinds of sports, and doesn’t enjoy running anymore, although he does it anyway.
Academic Credentials
PhD in Psychology from Stanford University, post-doctoral research in neurophysiology at Yale University
